What is CraniUS?
CraniUS is a pioneering neurotechnology and medical device firm dedicated to developing advanced systems for direct drug delivery to the brain. Its core innovation, the implantable NeuroPASS platform, is engineered to circumvent the blood-brain barrier, enabling targeted therapeutic interventions for debilitating neurological disorders. The company's focus areas include brain tumors, Alzheimer disease, and Parkinson disease, positioning it at the forefront of precision medicine for the central nervous system.
How much funding has CraniUS raised?
CraniUS has raised a total of $39.4M across 2 funding rounds:
Series A
$19.4M
Series B
$20M
Series A (2022): $19.4M, investors not publicly disclosed
Series B (2026): $20M led by State of Maryland
Key Investors in CraniUS
State of Maryland
The State of Maryland, through its official government portal, likely supports innovative ventures within its jurisdiction, potentially focusing on healthcare and technology advancements that benefit its citizens.
What's next for CraniUS?
The recent major strategic investment signals CraniUS's transition into a scaling phase, likely aimed at accelerating product development, expanding clinical trials, and preparing for broader market penetration. This capital infusion is expected to bolster the company's efforts in refining its NeuroPASS technology and demonstrating its efficacy across a spectrum of neurological diseases. Future endeavors will likely involve forging strategic partnerships within the healthcare ecosystem and navigating the complex regulatory pathways for novel medical devices.
See full CraniUS company page
